A new study has for the first time elucidated the gut-liver immune regulatory axis jointly maintained by intestinal commensal bacteria and the intestinal endocrine system, and uncovered the fundamental mechanism underlying the body's nonspecific clearance of drug delivery carriers. It provides a universal solution to the core problem plaguing the delivery field for decades, significantly improves the delivery efficiency and therapeutic effect of tumor-targeted therapy, mRNA therapy, gene editing and other treatments, and blazes a new trail for the clinical translation of biomedical delivery technologies.
